clinical trial · NCT02130362
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
AbbVie·—·active not recruiting·n = 1,446
Crohn's Disease
brief summary
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
started
Aug 28, 2014
primary completion
Nov 1, 2030
completion
Nov 1, 2030
last updated
Jul 16, 2025
official title
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol